The drug lenacapavir is a mighty weapon against HIV. Its rollout gets mixed reviews

A New Era of HIV Prevention Takes Root in Uganda

Lenacapavir’s Promise Meets Real-World Challenges

Ecorescuezone.com – Along the dusty red dirt roads winding through central Uganda’s Lake Victoria coastline, banana groves stretch as far as the eye can see. Markets bustle with vendors selling fresh produce, and the landscape remains largely unchanged for miles. Yet this seemingly ordinary region has become a testing ground for one of medicine’s most promising advances against HIV.

Lenacapavir, an injectable medication administered just twice a year, represents a quantum leap in HIV prevention. Unlike traditional daily pills that require consistent adherence, this new treatment offers protection through a single injection that slowly releases into the body over months. For communities where stigma and access barriers have long complicated HIV care, the drug offers renewed hope.

A Personal Story of Prevention

Irene, a 22-year-old resident of the area, has witnessed the challenges of living with HIV firsthand. Her uncle, who has lived with the virus for years, has experienced severe illnesses and significant weight loss. His struggles motivated her to join a groundbreaking clinical trial three years ago.

“I can see that his life is so hard. Like he gets strong illnesses and even right now he’s so slim,” Irene explained. “Once you get it, your life changes for the worse.”

She requested that only her first name be used, concerned that community members might assume she has HIV simply because she participates in a trial. Her fears are not unfounded—participating in HIV research in close-knit Ugandan communities can sometimes lead to unwanted assumptions about one’s health status.

Now, with her baby due in just three weeks, Irene feels confident that HIV is no longer a threat. She lives in a district where approximately 13 percent of residents carry the virus. Thanks to lenacapavir, she has been protected without the burden of daily medication.

How Lenacapavir Works

Lenacapavir functions as pre-exposure prophylaxis, or PrEP, for HIV-negative individuals seeking to prevent infection. The medication is injected directly into the abdomen, where it releases gradually over time. Participants at trial sites receive their injection only twice annually, a dramatic reduction from the daily pill regimen of traditional PrEP.

An oral version of the drug exists but requires more frequent dosing, making the injectable form particularly valuable for populations where daily adherence remains challenging. The medication’s mechanism targets multiple stages of the HIV lifecycle simultaneously, creating a robust defense against the virus.

“Lenacapavir is like having security guards stationed throughout the building, ready to ‘catch’ an intruder at various points,” Dr. Flavia Matovu Kiweewa explained. “Other HIV prevention drugs are more like guards who man just one entrance.”

Dr. Matovu Kiweewa serves as director of research at the Makerere University-Johns Hopkins University Research Collaboration, where she led the PURPOSE 1 trial in Uganda. Her analogy captures why lenacapavir differs fundamentally from earlier prevention medications.

Unprecedented Trial Results

The clinical trials examining lenacapavir—PURPOSE 1 and PURPOSE 2—delivered remarkable findings that surprised even experienced researchers. After two years of data collection, an independent monitoring committee determined the drug was so effective that both trials should conclude their randomized phases early. It was no longer ethically sound to withhold the medication from participants receiving placebo injections.

PURPOSE 1 focused exclusively on women, who constitute the majority of new HIV infections across sub-Saharan Africa. Nearly 4,200 women participated in the trial. The results were striking: more than 96 percent of participants received their injections on schedule, and none of the women acquired HIV during the period after everyone was offered lenacapavir.

Additional data presented at the International AIDS Conference in July revealed that protection remained equally strong one year after participants received the drug. The sustained efficacy suggests lenacapavir could transform prevention strategies globally.

PURPOSE 2 enrolled men and gender-diverse individuals who have sex with men. Adherence rates were slightly lower in this group, and one participant contracted HIV. Nevertheless, the results reinforced the drug’s potential across diverse populations.

Rollout Challenges and Global Implications

Despite the enthusiasm surrounding lenacapavir, its initial distribution has encountered mixed reception. When oral PrEP first received approval in the United States in 2012, it required three years to reach sub-Saharan Africa. An additional five years passed before the medication became widely accessible throughout the region.

Gilead Sciences, the pharmaceutical company responsible for developing lenacapavir, also brought oral PrEP to market. The company’s experience with the earlier medication provides both lessons and expectations for the newer treatment.

The U.S. Food and Drug Administration approved lenacapavir last year for HIV prevention in negative individuals. The agency also granted access for patients with multi-drug-resistant HIV, recognizing that the drug’s ability to target multiple replication stages makes it valuable even when other treatments fail.

Dr. Matovu Kiweewa emphasized that the results achieved with lenacapavir are historically significant. Daily pill adherence has always been a fundamental challenge in HIV prevention. Individuals who fear stigma from partners knowing they take medication, or who struggle with prescription access, often miss doses. Even a few missed doses each week can substantially reduce PrEP effectiveness.

The twice-yearly injection eliminates many of these barriers. Communities in Uganda and beyond are now evaluating how to integrate lenacapavir into existing healthcare systems, ensuring that the drug’s promise translates into real-world protection for those who need it most.